Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.57 |
| ▸ | ACE | P12821 | 3/20 | 0.57 |
| ▸ | CYP11B1 | P15538 | 9/20 | 0.53 |
| ▸ | CYP11B2 | P19099 | 9/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | FPR2 | P25090 | 1/20 | 0.42 |
| ▸ | FNTA | P49354 | 5/20 | 0.39 |
| ▸ | FNTB | P49356 | 5/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5870580 | 0.87 | ACE2 (0.74) | ACE2ACECYP11B1CYP11B2PKM | |
| SCHEMBL5870574 | 0.87 | ACE2 (0.74) | ACE2ACECYP11B1CYP11B2PKM | |
| SCHEMBL5869482 | 0.87 | ACE2 (0.74) | ACE2ACECYP11B1CYP11B2PKM | |
| SCHEMBL7222176 | 0.85 | ACE2 (0.77) | ACE2ACECYP11B1CYP11B2FNTA | |
| SCHEMBL8258457 | 0.85 | ACE2 (0.67) | ACE2ACECYP11B1CYP11B2PKM | |
| SCHEMBL8249070 | 0.84 | ACE (0.58) | ACE2ACECYP11B1CYP11B2FNTA | |
| SCHEMBL5869812 | 0.84 | ACE (0.58) | ACE2ACECYP11B1CYP11B2FNTA | |
| SCHEMBL5869936 | 0.83 | ACE2 (0.59) | ACE2ACECYP11B1CYP11B2FNTA | |
| SCHEMBL8248307 | 0.81 | ACE2 (0.62) | ACE2ACECYP11B1CYP11B2PKM | |
| SCHEMBL7222649 | 0.81 | ACE2 (0.62) | ACE2ACECYP11B1CYP11B2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | claimed |
| US-11337909-B2 | Methods for modulating pigmentation by angiotensin-converting enzyme 2 modulation | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT (DE) | 2022-05-24 | — | — | US | disclosed |
| US-20200360258-A1 | METHODS FOR MODULATING PIGMENTATION BY ANGIOTENSIN-CONVERTING ENZYME 2 MODULATION | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT (DE) | 2020-11-19 | — | — | US | disclosed |
| EP-3717077-A1 | METHODS FOR MODULATING PIGMENTATION BY ANGIOTENSIN-CONVERTING ENZYME 2 MODULATION | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft (DE) | 2020-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | ACE, ACE2, AGTR2 | ACE2 2/4885ACE 1/4885CYP11B1 256/4885 |
| US-20200360258-A1 | METHODS FOR MODULATING PIGMENTATION BY ANGIOTENSIN-CONVERTING ENZYME 2 MODULATION | ACE, ACE2, TYR | ACE2 2/4885ACE 1/4885CYP11B1 1239/4885 |
| US-11337909-B2 | Methods for modulating pigmentation by angiotensin-converting enzyme 2 modulation | ACE, ACE2, TYR | ACE2 2/4885ACE 1/4885CYP11B1 1239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.